New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19.
Is clinical development prepared for the paradigm shift caused by COVID-19?
The COVID-19 pandemic has – without warning – turned clinical operations on its head, forcing the clinical research community to re-evaluate how to manage clinical trials. In this new environment, many organizations have accelerated their plans to shift to a decentralized clinical trial model.
With this transition comes many benefits and challenges, and begs the question: are clinical development organizations prepared for this paradigm shift?
Biopharmaceutical companies, medical device companies, and contract research organizations (CROs) from around the world were surveyed to explore the impact of the current environment on clinical trial management, providing invaluable insight into:
Offered Free by: Oracle Health Sciences
See All Resources from: Oracle Health Sciences
This download should complete shortly. If the resource doesn't automatically download, please, click here.